medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2026, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2026; 24 (1)

Coexistence of androgenetic alopecia and alopecia areata: a case report

Borraz NMA

Language: Spanish
References: 22
Page: 73-78
PDF size: 438.58 Kb.


ABSTRACT

Alopecia is defined as the absence or loss of hair in areas where it is normally present. It stands as one of the most common reasons for trichological consultation and is frequently associated with psychological distress including anxiety and depression, which significantly diminishes the patient’s quality of life. Both androgenetic alopecia (AGA) and alopecia areata (AA) are primary etiologies of non-scarring hair loss. While often regarded as distinct entities, current evidence suggests that their coexistence is not uncommon, potentially complicating both the diagnostic approach and therapeutic response. We present the case of a 44-year-old male with an 8-month history of hair loss in the occipital region. Clinical and trichoscopic features revealed the simultaneous presence of AGA and AA. A combined treatment regimen utilizing topical and oral minoxidil, alongside topical and oral steroids and methotrexate, successfully led to hair regrowth in the affected areas. In the discussion, we analyze the shared characteristics of these conditions, the pivotal role of diagnostic trichoscopy, and integrated treatment strategies.


REFERENCES

  1. Al Aboud AM, Syed HA, Zito PM. Alopecia. [Actualizado 26 feb 2024]. En: StatPearls [Internet]. Treasure Island (FL): StatPearlsPublishing; 2025 ene-. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK538178/

  2. Martinez-Lopez A, Montero-Vilchez T, Sierra-Sánchez Á,Molina-Leyva A, Arias-Santiago S. Advanced Medical Therapiesin the Management of Non-Scarring Alopecia: Areata andAndrogenic Alopecia. Int J Mol Sci. 2020;21(21):8390.

  3. Tamashunas NL, Bergfeld WF. Male and female pattern hair loss:Treatable and worth treating. Cleve Clin J Med. 2021;88(3):173-182.

  4. Olsen EA, Bergfeld WF, Cotsarelis G, Price VH, Shapiro J,Sinclair R, et al. Summary of North American Hair ResearchSociety (NAHRS) workshop on cicatricial alopecia, DukeUniversity Medical Center, February 10-11, 2001. J Am AcadDermatol. 2003;48(1):103-110.

  5. Fanti PA, Baraldi C, Misciali C, Piraccini BM. Cicatricial alopecia.G Ital Dermatol Venereol. 2018;153(2):230-242.

  6. Vañó-Galván S, Saceda-Corralo D, Blume-Peytavi U, Cucchía J,Dlova NC, Gavazzoni Dias MFR, et al. Frequency of the Typesof Alopecia at Twenty-Two Specialist Hair Clinics: A MulticenterStudy. Skin Appendage Disord. 2019;5(5):309-315.

  7. Rodríguez-Serrano MD. Alopecia androgenética: revisiónde tratamientos y nuevas opciones terapéuticas. DermatolCosmet Med Quir. 2021;19(4):369-375.

  8. Tosti A, Asz-Sigall D, Pirmez R. Tratamientos del cabello y elcuero cabelludo, Guía Práctica. 1a ed. Ciudad de México:Amolca; 2023. Cap. 8, Alopecia Androgénica; p. 91-108.

  9. Premanand A, Reena Rajkumari B. Androgen modulationof Wnt/β-catenin signaling in androgenetic alopecia. ArchDermatol Res. 2018;310(5):391-399.

  10. Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al.Androgenetic alopecia: a review. Endocrine. 2017;57(1):9-17.

  11. Arenas R. Dermatología: atlas, diagnóstico y tratamiento. 8aed. Ciudad de México: McGraw Hill; 2024. Cap. 134, AlopeciaAreata; p.654-657.

  12. Habif TP. Clinical Dermatology: A color guide to diagnosisand therapy. 7a ed. Edimburgo: Elsevier; 2020. Cap. 24, HairDiseases; p.942-947.

  13. Peters EM, Liotiri S, Bodó E, Hagen E, Biolat M, Rose M,et al. Probing the effects of stress mediators on the humanhair follicle: substance P holds central position. Am J Pathol.2007;171(6):1872-1886.

  14. Azzawi S, Penzi LR, Senna MM. Immune Privilege Collapse andAlopecia Development: Is Stress a Factor? Skin AppendageDisord. 2018;4(4):236-244.

  15. Ito T, Ito N, Saathoff M, Bettermann A, Maderson P, Soma T,et al. Interferon-gamma is a potent inducer of catagen-likechanges in cultured human anagen hair follicles. Br J Dermatol.2005;152(4):623-631.

  16. Tosti A, Asz-Sigall D, Pirmez R. Tratamientos del cabello y elcuero cabelludo, Guía Práctica. 1a ed. Ciudad de México:Amolca; 2023. Cap. 8, Alopecia Areata; p. 109-121.

  17. Alessandrini A, Starace M, Bruni F, Brandi N, Baraldi C, MiscialiC, et al. Alopecia Areata Incognita and Diffuse Alopecia Areata:Clinical, Trichoscopic, Histopathological, and TherapeuticFeatures of a 5-Year Study. Dermatol Pract Concept.2019;9(4):272-277.

  18. Inui S, Nakajima T, Itami S. Significance of dermoscopy in acutediffuse and total alopecia of the female scalp: review of twentycases. Dermatology. 2008;217(4):333-336.

  19. Rebora A. Alopecia areata incognita: a hypothesis.Dermatologica. 1987;174(5):214-218.

  20. Rahardja JI, Ruchiatan K, Hindritiani R. Concomitantandrogenetic alopecia and alopecia areata successfully treatedwith a combination of topical corticosteroids and minoxidilsolution: A case report. 23rd Asia-Pacific DermatologyConference; 2017 oct 26-28; Osaka, Japón.

  21. Starace M, Vezzoni R, Alessandrini A, Bruni F, Carpanese MA,Misciali C, et al. Therapeutic approach with squaric aciddibutylester for steroid resistant-alopecia areata incognita:a pilot study of a single center. Dermatol Ther. 2021;34(5):e15096.

  22. Rodríguez-Tamez G, Maskan-Bermudez N, Tosti A. AlopeciaAreata Incognita: Current Evidence. Dermatol Ther (Heidelb).2025; 15:635-645.




2020     |     www.medigraphic.com